|
ZXDA expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.99200722162641E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.1094237467878E-15 |
| Normal-vs-Stage2 |
9.41469124882133E-13 |
| Normal-vs-Stage3 |
1.62470037423645E-12 |
| Normal-vs-Stage4 |
1.62503344114384E-12 |
| Stage1-vs-Stage2 |
7.073800E-01 |
| Stage1-vs-Stage3 |
2.215400E-01 |
| Stage1-vs-Stage4 |
1.884990E-01 |
| Stage2-vs-Stage3 |
2.588600E-01 |
| Stage2-vs-Stage4 |
1.850800E-01 |
| Stage3-vs-Stage4 |
7.411000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62525548574877E-12 |
| Normal-vs-AfricanAmerican |
1.8461999706787E-09 |
| Normal-vs-Asian |
1.66655578226482E-12 |
| Caucasian-vs-AfricanAmerican |
2.749200E-01 |
| Caucasian-vs-Asian |
9.545400E-01 |
| AfricanAmerican-vs-Asian |
3.619600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62470037423645E-12 |
| Normal-vs-Female |
1.62614366416847E-12 |
| Male-vs-Female |
3.322600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62625468647093E-12 |
| Normal-vs-Age(41-60Yrs) |
9.99200722162641E-16 |
| Normal-vs-Age(61-80Yrs) |
8.88178419700125E-16 |
| Normal-vs-Age(81-100Yrs) |
1.206630E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.367600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.879200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.646800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.114200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.146200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.126000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.136000E-03 |
| Classical-VS-Follicular |
3.813000E-01 |
| Classical-VS-Other |
9.605900E-02 |
| Classical-VS-Normal |
1.67466041034459E-12 |
| Tall-VS-Follicular |
6.945900E-02 |
| Tall-VS-Other |
5.412600E-01 |
| Tall-VS-Normal |
1.62458935193399E-12 |
| Follicular-VS-Other |
2.310000E-01 |
| Follicular-VS-Normal |
2.28705943072782E-14 |
| Other-VS-Normal |
4.68070000003706E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62569957495862E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
7.891700E-02 |
|
|
